Abstract
A masterclass initiated, organised, and funded by UCB, sought to advance understanding and expertise of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
MOGAD is a rare central nervous system (CNS) inflammatory disorder. It has only relatively recently been characterised as a separate entity to similar demyelinating conditions, such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Differentiating MOGAD from MS and NMOSD can be challenging, but is essential to ensure a correct diagnosis in order to guide effective treatment and management.
An increase in the availability of cell-based assays (CBA) for detection of autoantibodies directed against myelin oligodendrocyte glycoprotein (MOG) over the last decade has provided healthcare professionals with an important new diagnostic tool. However, the approach has limitations in terms of sensitivity and specificity, meaning results must be considered alongside clinical characteristics and neuroimaging. A proposed diagnostic pathway by the international MOGAD panel, published in March 2023, sets out the core clinical demyelinating events that could suggest MOGAD, when MOG-IgG testing may be appropriate, and when supporting clinical or MRI features are required to confirm a diagnosis. These consensus criteria are now being evaluated by centres around the world.
This article will summarise the talks given by key opinion leaders from across Europe and the USA during the educational event. They discussed the pathology and presentation of MOGAD, how to integrate imaging into diagnostic pathways, and current management approaches. They also looked at possible future directions, in terms of novel treatment approaches.